Back to Sites

Emory University School of Medicine NICHD CRS

Site Number

5030

Address

Emory University School of Medicine
Department of Pediatrics
Division of Infectious Diseases
2015 Uppergate Drive
Atlanta, GA 30322
United States of America

IMPAACT Members at this Site

LaTeshia Thomas-Seaton CRS Coordinator

Bridget Wynn CRS Coordinator

Andrés Camacho-Gonzalez CRS Leader

Riaun Floyd CRS Staff

Sierra Jordan-Thompson CRS Staff

Studies at this Site

P1026S: PK in Pregnancy

DAIDS Number

Therapeutics

Research Area

Treatment

Study Status

Closed to Follow Up

P1110: Safety and PK of RAL in Neonates

DAIDS Number

11891

Research Area

Treatment

Study Status

Concluded

P1112: Monoclonal Antibody PK Study

DAIDS Number

11903

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States

DAIDS Number

12051

Research Area

Brain and Mental Health

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30072

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30073

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30074

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2015: Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults with Cognitive Impairment

DAIDS Number

35123

Research Area

Cure and Immunotherapy

Study Status

Concluded

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

38530

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Enrolling